YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

被引:1
作者
Lam, Wing [1 ]
Arammash, Mohammad [1 ]
Cai, Wei [1 ,2 ]
Guan, Fulan [1 ]
Jiang, Zaoli [1 ]
Liu, Shwu-Huey [3 ]
Cheng, Peikwen [3 ]
Cheng, Yung-Chi [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06511 USA
[2] Hunan Univ Med, Sch Pharmaceut Sci, Huaihua, Peoples R China
[3] Yiviva Inc, New York, NY USA
关键词
YIV-818-A; AR; GR; prostate cancer; apalutamide; darolutamide; and enzalutamide; ANTITUMOR CYCLIC HEXAPEPTIDES; SPLICE VARIANTS; PROTEIN-SYNTHESIS; RESISTANCE; MECHANISM; TRANSCRIPTION; BOUVARDIN; CISTROME; GROWTH;
D O I
10.3389/fphar.2023.1244655
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC is often driven by AR variants and glucocorticoid receptor (GR). Thus, drugs that target both could be vital in overcoming resistance.Methods: Utilizing the STAR Drug Discovery Platform, three hundred medicinal plant extracts were examined across 25 signaling pathways to identify potential drug candidates. Effects of the botanical drug YIV-818-A, derived from optimized water extracts of Rubia cordifolia (R.C.), on Dihydrotestosterone (DHT) or Dexamethasone (DEX) induced luciferase activity were assessed in 22RV1 cells harboring the ARE luciferase reporter. Furthermore, the key active compounds in YIV-818-A were identified through activity guided purification. The inhibitory effects of YIV-818-A, RA-V, and RA-VII on AR and GR activities, their impact on AR target genes, and their roles in modifying epigenetic status were investigated. Finally, the synergistic effects of these compounds with established CRPC drugs were evaluated both in vitro and in vivo.Results: YIV-818-A was found to effectively inhibit DHT or DEX induced luciferase activity in 22RV1 cells. Deoxybouvardin (RA-V) was identified as the key active compound responsible for inhibiting AR and GR activities. Both YIV-818-A and RA-V, along with RA-VII, effectively downregulated AR and AR-V proteins through inhibiting protein synthesis, impacted the expression of AR target genes, and modified the epigenetic status by reducing levels of Bromodomain and Extra-Terminal proteins (Brd2/Brd4) and H3K27Ac. Furthermore, these compounds exhibited synergistic effects with apalutamide, darolutamide, or enzalutamide, and suppressed AR mediated luciferase activity of 22RV1 cells. Co-administration of YIV-818-A and enzalutamide led to a significant reduction of 22RV1 tumor growth in vivo. Different sources of R.C. had variable levels of RA-V, correlating with their potency in AR inhibition.Discussion: YIV-818-A, RA-V, and RA-VII show considerable promise in addressing drug resistance in CRPC by targeting both AR protein and GR function, along with modulation of vital epigenetic markers. Given the established safety profile of YIV-818-A, these findings suggest its potential as a chemopreventive agent and a robust anti-prostate cancer drug.
引用
收藏
页数:13
相关论文
共 41 条
  • [1] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Mohammad, Tabrez A.
    Chen, Yidong
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 1028 - 1038
  • [2] Mechanisms and Approaches for Overcoming enzalutamide Resistance in Prostate Cancer
    Ark, Alexandra Vander
    Cao, Jingchen
    Li, Xiaohong
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    Arora, Vivek K.
    Schenkein, Emily
    Murali, Rajmohan
    Subudhi, Sumit K.
    Wongvipat, John
    Balbas, Minna D.
    Shah, Neel
    Cai, Ling
    Efstathiou, Eleni
    Logothetis, Chris
    Zheng, Deyou
    Sawyers, Charles L.
    [J]. CELL, 2013, 155 (06) : 1309 - 1322
  • [4] Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
    Asangani, Irfan A.
    Dommeti, Vijaya L.
    Wang, Xiaoju
    Malik, Rohit
    Cieslik, Marcin
    Yang, Rendong
    Escara-Wilke, June
    Wilder-Romans, Kari
    Dhanireddy, Sudheer
    Engelke, Carl
    Iyer, Mathew K.
    Jing, Xiaojun
    Wu, Yi-Mi
    Cao, Xuhong
    Qin, Zhaohui S.
    Wang, Shaomeng
    Feng, Felix Y.
    Chinnaiyan, Arul M.
    [J]. NATURE, 2014, 510 (7504) : 278 - +
  • [5] Control of cell cycle transcription during G1 and S phases
    Bertoli, Cosetta
    Skotheim, Jan M.
    de Bruin, Robertus A. M.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (08) : 518 - 528
  • [6] Buchanan G, 2001, CLIN CANCER RES, V7, P1273
  • [7] Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
    Cattrini, Carlo
    Caffo, Orazio
    De Giorgi, Ugo
    Mennitto, Alessia
    Gennari, Alessandra
    Olmos, David
    Castro, Elena
    [J]. CANCERS, 2022, 14 (07)
  • [8] Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles
    Chan, J
    Khan, SN
    Harvey, I
    Merrick, W
    Pelletier, J
    [J]. RNA, 2004, 10 (03) : 528 - 543
  • [9] CHOU TC, 1977, J BIOL CHEM, V252, P6438
  • [10] Molecular mechanisms underlying RB protein function
    Dick, Frederick A.
    Rubin, Seth M.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (05) : 297 - 306